<DOC>
	<DOC>NCT01852435</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety and efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell lymphoma and Follicular Lymphoma Grade 3B patients.</brief_summary>
	<brief_title>R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B</brief_title>
	<detailed_description>The study aims to evaluate the safety and efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell lymphoma and Follicular Lymphoma Grade 3B patients.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Follicular</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<criteria>1. Histologically confirmed de novo diffuse large Bcell lymphoma or follicular lymphoma grade 3B 2. Age&gt;=16 y.o.,&lt;=80 y.o. 3. ECOG &lt; 3 4. No past history of malignancy 5. Radiologically measurable disease, CT imaging in screening showing 2 or more clearly demarcated lesions with a largest diameter &gt; 1.5 cm, or 1 clearly demarcated lesion with a largest diameter &gt; 2.0 cm. 6. Life expectancy&gt;6 months 7. Informed consented 1. Chemotherapy before 2. Bone marrow transplantation before 3. History of malignancy 4. Active infectious disease requiring general antibiotics, antifungal or antivirus therapy 5. Uncontrollable cardiocerebral vascular, coagulative, autoimmune, serious infectious disease 6. Primary cutaneous, CNS, mediastinal DLBCL 7. LVEFâ‰¤50% 8. Other uncontrollable medical condition that may that may interfere the participation of the study 9. Lab at enrollment(unless caused by lymphoma) Neutrophile&lt;1.5*10^9/L Platelet&lt;80*10^9/L Hemoglobulin&lt;100g/L ALT or AST &gt;2*ULN,AKP or bilirubin &gt;1.5*ULN Creatinine&gt;1.5*ULN 10. Not able to comply to the protocol for mental or other unknown reasons 11. Pregnant or lactation 12. Active liver or biliary disease 13. If HbsAg positive, should check HBV DNA, DNA positive patients cannot be enrolled. If HBsAg negative but HBcAb positive (whatever HBsAb status), should check HBV DNA,DNA positive patients cannot be enrolled. 14. HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>diffuse large B-cell lymphoma</keyword>
	<keyword>follicular lymphoma grade 3B</keyword>
</DOC>